Pharmamel

Pharmamel, S.A. is a biotech R&D company, a spin-off from the University of Granada and the Andalusian Health Service, specialized in the development of innovative melatoninbased drugs. Its projects focus on diseases associated with systemic inflammation, oxidative stress, and cellular damage, with a particular emphasis on sepsis and
mucositis.

The company has developed an intravenous melatonin injectable for the treatment of sepsis, a condition with no specific therapy and high global mortality validated in Phase II clinical trials and currently progressing toward Phase II/III clinical development. It has also developed an oral melatonin gel for mucositis in oncology patients, likewise
clinically validated.

With more than 30 years of research transferred from the University of Granada to the company and two patented drugs in advanced stages of development, Pharmamel positions itself as a European benchmark in innovative melatonin-based therapies, actively seeking strategic partners to complete development and bring these projects to market.